If you have been reading about albumin conjugate and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The colony's participation in the Empire Air Training Scheme is described in J F MacDonald's War History of Southern Rhodesia as "undoubtedly Southern Rhodesia's greatest single contribution to the Allied victory", an assertion corroborated by Robert Blake in his 1977 History of Rhodesia. The Rhodesian Air Training Group (RATG) under Air Vice-Marshal Sir C W Meredith eventually operated 11 aerodromes, requiring a huge national effort to build, maintain and staff—at the scheme's peak more than a fifth of the white population was involved. This judicious management of skills and resources allowed the territory to make a much larger contribution to the Allied war effort than if it had simply sent all its manpower into the field. Southern Rhodesia was regarded as an ideal location for air training for a number of reasons. It was far from the hostilities, firmly pro-British and had excellent weather throughout the year. The British Air Ministry resolved to outsource training to the colony amid some urgency in late 1939 after EATS took a long time to get going in Canada. The RATG was the last EATS group to be formed, but the first to start training airmen; it also turned out fully qualified pilots before any of the others, doing so for the first time in November 1940. The programme originally called only for an initial training wing and six schools, but this was expanded to eight flying schools and a school for bomb aimers, navigators and air gunners. There were two air firing and bombing ranges.
=== Market characteristics === Bitcoin markets operate 24 hours a day, seven days a week, contrasting with traditional financial markets that have fixed trading hours. Bitcoin prices show much higher volatility and respond strongly to both regulatory changes and market events. The volume of bitcoin trading can fluctuate considerably among various exchanges and geographic regions. The daily transaction volume of bitcoin across all exchanges typically reaches $50 billion as of 2025.
==== Commander of the Order of the British Empire (CBE) ==== Military Division Royal Navy Captain Paul Branscombe, . Captain William Keith Hutchison. Captain Keith Frank Read. Army Major General Cedric Norman George Delves, , (485712), late The Devonshire and Dorset Regiment. Brigadier Kevin John Watson Goad, , (472543), late Royal Army Ordnance Corps. Colonel (Acting Brigadier) Keith Skempton (487055), late The Cheshire Regiment. Colonel (Acting Brigadier) Albert Edward Whitley, , (495259), late Corps of Royal Engineers. Royal Air Force Group Captain Roger Hubert Beazley, , (Retired). Group Captain George William Gibson, (Retired). Air Commodore Ernest William Tyack. Civil Division John Edwin Adshead. For services to the National Training Awards and to Vocational Training. Nicholas Kenneth Alston, Assistant Secretary, Ministry of Defence. Michael Day Beaumont, . For political and public service. Arthur John Armstrong Bell. For political and public service. Alastair John Bellingham, Professor of Haematology, King's College Hospital School of Medicine and Dentistry. For services to Medicine and to the Royal College of Pathologists. Professor Sushantha Kumar Bhattacharyya, Professor of Manufacturing Systems Engineering, University of Warwick. For services to Industry and to Technology. John David Stuart Brown, . For political and public service. Christopher John Skidmore Burd. For services to the Forestry Industry. David Thomas Burke, Expert Special Adviser on the Environment, Department of the Environment. David Adam Cairns, Music Critic, The Sunday Times.
Sources: en.wikipedia.org
Molecular medicine (the broader field of the molecular understanding of disease) Molecular pathology Laboratory Developed Test Pathogenesis Pathogenomics Pathology Precision medicine Personalized medicine
RCO2R' + NH2R″ → RCONHR″ + R'OH This reaction is not usually reversible. Hydrazines and hydroxylamine can be used in place of amines. Esters can be converted to isocyanates through intermediate hydroxamic acids in the Lossen rearrangement. Sources of carbon nucleophiles, e.g., Grignard reagents and organolithium compounds, add readily to the carbonyl.
==== Components ==== Water: Water makes up around 80% of cartilage. Chondrocytes: Chondrocytes are the cells that produce and maintain the cartilaginous matrix. They are sparsely dispersed throughout cartilage and make up only about 2% of the total volume of cartilage. Chondrocytes vary in size, shape and concentration depending on their location in articular cartilage. Collagen: Collagen is a structural protein present in the extracellular matrix of cartilage. Collagen is composed of a triple helix structure of polypeptide chains and offers shear and tensile properties to the cartilage. Type II collagen is the most common type of collagen present in cartilage though types IX, X, XI, and XIV are also present. Overall, collagen is a stabilizing protein present in the ECM. Proteoglycans: Proteoglycans are the second most abundant macromolecule in the ECM of cartilage. Proteoglycans consist of a linker protein along with a core protein to which glycosaminoglycans (GAGs) attach. The most common GAGs are chondroitin sulfate and keratin sulfate. Proteoglycans attach to a central chain, usually hyaluronic acid, via a linker protein, to create larger proteoglycan aggregates. Proteoglycans are hydrophilic and therefore attract and restrain water molecules. This provides cartilage with its intrinsic ability to resist compression. Glycoproteins: Many other glycoproteins are present in cartilage ECM in small amounts that help maintain structure and organization. Specifically, lubricin helps to create a lubricating surface on the cartilage for easier joint mobility.
== Usefulness of NTX as a biomarker == Evaluating an individual's rate of bone turnover, termed bone remodeling, directly may be important in assessing his or her potential nonsurgical treatment response as well as evaluating his or her risk of developing complications during healing following surgical intervention. To determine an individual's rate of bone turnover, numerous biomarkers are available in the body fluids that can be correlated to this rate, and one such biomarker is NTX. However, while NTX does fluctuate in a very sensitive manner in line with bone resorption patterns, they are not very specific, in that they may vary spontaneously without physiologic intervention. For example, NTX levels may drop by 50% from day to day with no treatment, thus, making NTX levels unconvincing evidence of treatment effect. Conversely, the serum CTX biomarker, described in 2000 by Rosen, appears to be a much more effective and valuable indicator of bone resorption rate.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.